Research group looking to bring Cuba's lung cancer vaccine to the United States
the ONA take:
As relations between the United States and Cuba normalize, groundbreaking lung cancer research and a vaccine may be early imports from the island nation.
A group that included from Roswell Park Cancer Institute’s (RPCI) president and CEO and New York Governor Andrew Cuomo met in face-to-face meetings with representatives and researchers from Cuba’s Center for Molecular Immunology (CIM) in which they finalized an agreement to bring CimaVax, the CIM’s lung cancer vaccine, to the United States.
CimaVax targets a growth factor (EGF) necessary for lung cancer to survive. By depleting the growth factor, the vaccine starves the cancer and slows its progression, prolonging patients’ lives.
Expansive clinical trials with published data show the vaccine effectively prolonged life, especially among patients younger than 60 years, compared with standard care, with minimal vaccine-related toxicity. The vaccine is administered as an injection in the shoulder once per month.
RPCI is preparing the paperwork for the FDA, and is hoping the FDA can begin its inspection within the next 2 to 3 months.
In addition, extensive safety data is currently available and may enable investigators to skip straight to a phase II study in patients. The researchers estimate the clinical trials, FDA approval, and other regulatory requirements would take 5 years to complete.
CimaVax is the first of several other potential collaborations between RPCI and CIM. Additional collaborations include potential use of CimaVax on colon, head and neck, prostate, breast, and pancreatic cancers, and a second vaccine that targets blood cancers.
As relations between the United States and Cuba normalize, groundbreaking lung cancer research and a vaccine may be early imports.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|